Galbanic acid suppresses melanoma cell migration and invasion by reducing MMP activity and downregulating N-cadherin and fibronectin

Azad, Masoumeh; Hosseini, Fatemehsadat; Hassanzade, Halimeh; Gharedaghi, Shahin; Mahdipour, Elahe; Rassouli, Fatemeh B.; Jamialahmadi, Khadijeh

doi:10.1007/s00210-024-02981-4

Cited by 1 publication

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 Noteworthy in this aspect of melanoma, the growing and promising strand of phytotherapeutic research focusing on the identification of natural compounds that, among the various pharmacological effects, have revealed remarkable inhibitory activity toward MMP2. [46][47][48][49][50][51] On the other hand, the controversial and dual role of MMP2 emerges from its association with improved overall survival rates in melanoma patients with a higher mutation burden due to its activity of freeing extracellular matrix (ECM) structural protein mutants adjacent to MMP2-sensitive sites. The high-affinity interaction with Human leukocyte antigens (HLA) class I molecules would promote antitumor T cell immune response.…”

Section: Mmp-2mentioning

confidence: 99%

Alarmins in cutaneous malignant melanoma: An updated overview of emerging evidence on their pathogenetic, diagnostic, prognostic, and therapeutic role

Papa,

Li Pomi,

Borgia

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

Malignant cutaneous melanoma is the leading cause of death for skin cancer to date, with globally increasing incidence rates. In this epidemiological scenario, international scientific research is exerting efforts to identify new clinical strategies aimed at the prognostic amelioration of the disease. Very promising and groundbreaking in this context is the scientific interest related to alarmins and their pioneering utility in the setting of the pathogenetic understanding, diagnosis, prognosis, and therapy for malignant cutaneous melanoma. However, the scientific investigations on this matter should not overlook their still well‐presented dual and contradictory role. The aim of our critical analysis is to provide an up‐to‐date overview of the emerging evidence concerning the dichotomous role of alarmins in the aforementioned clinical settings. Our literature revision was based on the extensive body of both preclinical and clinical findings published on the PubMed database over the past 5 years. In addition to this, we offer a special focus on potentially revolutionary new therapeutic frontiers, which, on the strength of their earliest successes in other clinical areas, could inaugurate a new era of personalized and precision medicine in the field of dermato‐oncology.

show abstract